Methamphetamine (METH) abuse is linked to significant hepatic injury, driven by oxidative stress, inflammatory pathway activation, autophagic dysregulation, and apoptosis induction. This study explored the hepatoprotective and anti‐inflammatory potential of the brown seaweed
Hormophysa cuneiformis
extract against METH‐induced liver damage in adult male Wistar rats.
Extracts prepared using methanol, ethanol, hexane, and water were screened for antioxidant activity. The methanolic extract, selected for further investigation, was characterized by phytochemical analysis and GC–MS profiling. Molecular docking was performed to evaluate the interactions of the identified bioactive compounds with TNF‐α and LC3B‐II. The cytotoxicity and selectivity of the methanolic extract were assessed using HepG‐2 hepatocellular carcinoma and WI‐38 normal cells. Its hepatoprotective effects were further evaluated in vivo in METH‐treated adult male Wistar rats using biochemical, Western blot, immunohistochemical, and histopathological analyses.
The methanolic extract showed the greatest antioxidant activity, achieving 57.16% ± 1.96% DPPH radical scavenging and 54.71% ± 0.84% ferric‐reducing antioxidant power. Although these values were lower than those of ascorbic acid (97.23 ± 0.48%), the methanolic extract exhibited higher antioxidant potential than the other extracts. Secondary metabolites, including alkaloids, saponins, tannins, and total phenolic compounds, were detected in notable amounts. GC‐MS analysis identified oleic acid, palmitic acid, linoleic acid, and arachidonic acid as the major constituents. The extract exhibited dose-dependent cytotoxicity against HepG–2 cells, with an IC50 of 77.14 ± 1.63 µg mL
−1
, while showing lower toxicity toward WI-38 cells (CC50 = 141.99 ± 3.54 µg mL
−1
), indicating selective antiproliferative activity and a favorable safety margin. In vivo, METH administration significantly elevated serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) levels. Oral co-treatment with the
H. cuneiformis
methanolic extract (15 mg kg
−1
) significantly attenuated METH-induced hepatocellular injury, lowering serum ALT from 89.33 to 54.33 U L
−1
, AST from 294.33 to 57.33 U L
−1
, and ALP from 264.67 to 189.00 U L
−1
. Western blot analysis showed that METH markedly increased LC3B-II and Beclin-1 expression, whereas co-administration of the extract significantly reduced both proteins. Immunohistochemical analysis also demonstrated increased caspase-3- and NF-κB-positive cells in the METH-treated group, which were significantly reduced following H. cuneiformis treatment.
Collectively, these findings suggest that
H. cuneiformis
exerts hepatoprotective effects against METH-induced liver injury through antioxidant, anti-inflammatory, anti-apoptotic, and autophagy-modulating mechanisms.
Mayada E. Elhusseiny, Rabab El-kelany, Rania A. El-Shenody et al.· Frontiers in Pharmacology· 0 citations
The global burden of infectious and non-communicable diseases presents a critical challenge, highlighting the urgent need for novel, safe, and effective therapies. Bioactive compounds from medicinal plants, especially flavonoids, offer a promising resource for drug discovery due to their diverse and potent pharmacological effects documented in preclinical studies. This comprehensive review summarizes current knowledge of flavonoids, including their classification into 14 main groups and their production via biosynthesis, chemical synthesis, modification, and extraction. While structural modification remains a key aspect of drug development, biosynthesis is increasingly seen as a potential transformative strategy for sustainable large-scale production. However, it requires a deeper understanding of metabolic pathways and optimization of synthetic methods. Aside from production challenges, a major translational hurdle is the inherently low bioavailability of many flavonoids. This review critically examines innovative solutions under investigation, such as advanced nanoparticles and colloidal drug delivery systems designed to address challenges in solubility, stability, and absorption. It also summarizes the current understanding of the mechanisms of action underlying their broad biological activities, primarily as evidenced by preclinical models, including nutritional, immunological, and disease-specific effects, and discusses potential drug interactions warranting clinical attention. Lastly, the review highlights key research gaps, including the need for more robust in vivo validation, standardized extracts to improve reproducibility, and well-designed clinical trials to verify efficacy in humans. Future directions include leveraging metabolic engineering and artificial intelligence to optimize biosynthesis, as well as targeted clinical studies of advanced delivery systems. By integrating these approaches, this review aims to establish a framework for ongoing research on flavonoids to inform future translational efforts that may eventually support their development as clinical therapies.
M. El-Saadony, A. Saad, Mohamed A. Fahmy et al.· Frontiers in Nutrition· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.